Other Events ·
Reports Q3 net loss of $19.4M; announces positive Phase 2 FREEDOM2-DM1 results with 46.5% splicing correction
PEPGPepGen Inc.
PepGen Inc. reported a third-quarter net loss of $19.4 million, or $0.28 per share, on November 10, 2026. The company also announced positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial for PGN-EDODM1 in myotonic dystrophy type 1 patients. Data showed a mean splicing correction of 46.5%, with five of six participants demonstrating greater than 20% improvement and four exceeding 50%. The treatment was generally well-tolerated with no serious adverse events or dose-limiting toxicities reported. PepGen holds $104.8 million in cash, sufficient to fund operations into 2028.